■ Abstract Advances in genotyping and sequencing technologies, coupled with the development of sophisticated statistical methods, have afforded investigators novel opportunities to define the role of sequence variation in the development of common human diseases. At the forefront of these investigations is the use of dense maps of single-nucleotide polymorphisms (SNPs) and the haplotypes derived from these polymorphisms. Here we review basic concepts of high-density genetic maps of SNPs and haplotypes and how they are typically generated and used in human genetic research. We also provide useful examples and tools available for researchers interested in incorporating haplotypes into their studies. Finally, we discuss the latest concepts for the analysis of haplotypes related to human disease, including haplotype blocks, the International HapMap Project, and the future directions of these resources.
SINGLE-NUCLEOTIDE POLYMORPHISMS

Discovery and Description
For several decades now, the workhorse of human genetics has been the DNA-based polymorphism (reviewed in Reference 1). Polymorphisms are often terminologically distinguished from mutations by an arbitrary frequency criterion: The different forms of the polymorphism (termed "alleles") are observed more often in the general population than mutations, with a population frequency of <1% often used as a cutoff value. The most common polymorphism in the human genome is the single-nucleotide polymorphism, better known as the SNP (pronounced "snip"). In samples of the size usually relevant to biomedical research, the vast majority of SNPs have two alleles, which represent a substitution of one base for another (e.g., C to T or A to G). For an individual SNP, one is designated the "major" allele and the other the "minor" allele based on their observed frequency in the general population. Because humans are diploid (chromosomes are maternal and paternal in origin), at a chosen SNP, a person can have one of several genotypes: homozygous for the major allele, heterozygous, or homozygous for the minor allele ( Figure 1a) .
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rare and occur only once ("singletons") or twice ("doubletons") in the sample of individuals examined. In fact, if one were to look across the human genome in the entire world population, every base compatible with life has been mutated. Based on these data, it is expected that there are approximately 6 million common SNPs in the human genome, many of which are already annotated in dbSNP. Common SNPs are of interest because it has been argued (31-34) that common genetic variation can explain a proportion of common human disease-the common variant/common disease (CV/CD) hypothesis. The definition of "common" depends on the application, but it ranges from a minor allele frequency of 5% to >20%. The subjective nature of this definition is apparent in the wide range of allele frequencies for common variants associated with common disease reported in the literature (reviewed in Reference 35).
Most SNPs do not occur in the coding region of genes or even in genes (9) , and of those that do occur in the coding region, even fewer change an amino acid within a protein (28, 30, 36 ). These few "nonsynonymous" SNPs have been targeted for further investigation in human disease because it is presumed that a change in amino acid will lead to a change in protein function. Deleterious changes such as missense and nonsense mutations are common causes of single-gene disorders and are also hypothesized to contribute to a proportion of common diseases (37). Because these SNPs directly affect protein function, many investigators advocate the genotyping of coding SNPs in genetic association studies (37); this strategy is known as a "direct" approach, as opposed to the "indirect" approach described below (33) . As the catalogue for nonsynonymous SNPs in the human genome develops, many computational tools are being developed to help investigators predict in silico which amino acid alterations will be deleterious (38-42).
Nonsynonymous SNPs, though obvious suspects in causing a proportion of human disease, do not account for all SNPs that can cause disease or susceptibility to disease. Other functional SNPs implicated in human disease or susceptibility to disease include SNPs located in promoters (43, 44), introns (45), splice sites (46), and intragenic regions (45, 47). Furthermore, even synonymous (or "silent") SNPs have been implicated as having functional consequences via unknown mechanisms (48). This latter finding highlights how little is known about the effects of DNA polymorphisms in relation to human disease.
HAPLOTYPES
Definition and Construction
Haplotypes are a combination of alleles at different markers along the same chromosome that are inherited as a unit. The fundamental difference between haplotypes and individual genotypes at SNPs is that the alleles are assigned to a chromosome. In essence, each individual has two haplotypes for a given stretch of the genome, representing the maternal and paternal chromosomes. To depict this visually, we can arbitrarily assign one allele at a SNP as the "major" (blue) allele and the other as the "minor" (yellow) allele (Figure 1b) . Thus, each haplotype is a combination of major and minor alleles along the chromosomes, and each individual is represented twice to account for the maternal and paternal contributions.
As we detail below, assignment of alleles to the chromosome (haplotypes) can be powerful because it yields information about recombination, which is the physical exchange of DNA during meiosis. Information about recombination is important for locating disease-causing mutations by linkage methods and has a profound effect on the extent of statistical associations between the presence of two SNPs in the genome, known as linkage disequilibrium-a key property for disease association studies across the human genome. Linkage disequilibrium can be thought of as an association between SNPs: Knowledge of the genotype at one SNP can predict the genotype of another SNP if the association (linkage disequilibrium) is high between these two SNPs.
There is much interest in developing methods to assign alleles to chromosomes because haplotypes are used by investigators to pinpoint the disease-causing locus by marking recombination events in both family-based and population-based studies. Currently, there are two broad categories of tools that can unambiguously determine haplotypes: directly genotyping pedigrees and using molecular methods in combination with genotyping for individual samples that do not have pedigree information (described in Table 1 ). The pedigree or family-based method relies on the fact that different loci on the same chromosome (haplotype) will be inherited as a unit unless they are separated by a recombination event. The probability of a recombination depends partly on the distance between the markers being examined. Markers that are close in physical distance have a greater probability of being "linked." Loci are said to be linked if their alleles travel together (cosegregate) when transmitted from parent to offspring as a haplotype. Recombination between two chromosomes will create two new haplotypes, which can potentially be transmitted to the next generation.
For population-based data, molecular or experimental methods have become the "gold standard" method for constructing haplotypes. Several molecular methods are available to construct unambiguous haplotypes. Two widely used molecular methods (Table 1) include allele-specific polymerase chain reaction (AS-PCR) and somatic cell hybrids (49, 50). These molecular methods distiguish which allele is on which chromosome, a step generally not required by family-based studies because this information can be extracted from knowledge of the alleles transmitted by the parents to the offspring. A common PCR reaction on an individual sample without pedigree information will tell the investigator what two alleles are present in an individual sample, but an allele-specific PCR will tell the investigator which allele is present in the context of another allele on the same chromosome. The somatic cell hybrid is a technique that physically separates the maternal and paternal chromosomes of an individual before genotyping. Both AS-PCR (51) and somatic cell hybrids (52) have been used to unambiguously determine haplotypes in relatively small to moderate-sized population surveys. Although pedigrees and molecular methods eliminate much of the ambiguity in assigning alleles to chromosomes, both tools are expensive and time-consuming. A less expensive and automated method for determining haplotypes from genotype data in large population-based surveys is statistical inference. Table 2 lists several of the statistical-inference sofware packages currently available (53). These haplotype inference programs can be categorized into three broad groups: parsimony (54) , maximum likelihood (55-57), and Bayesian (58, 59) . Each group has advantages and disadvantages. The Clark algorithm, based on parsimony, sets out to identify a minimum number of haplotypes consistent with the data by first identifying the known haplotypes (individuals who are homozygous for all sites and individuals who are heterozygous at only one site) and then searching for genotype combinations that are consistent with the known haplotypes. The Clark algorithm is easy to understand and use; however, the algorithm cannot be used on all datasets because they may not conform to the algorithm's requirements. For example, complex datasets may not have any individuals with unambiguous haplotypes, a requirement to start the algorithm. Also, the algorithm can leave many genotypes unassigned to haplotypes in large, complex datasets. The expectationmaximization (EM) algorithms overcome the limitations of the Clark algorithm in that they make an initial guess of the haplotype frequencies, and they are able to assign all alleles to haplotypes with a high probability. However, the EM algorithms do not make assumptions about recombination or mutation, they assume the data are in Hardy Weinberg equilibrium, and they are often computationally burdened by large datasets. Bayesian approaches, unlike the EM algorithms, incorporate assumptions or prior information as a guide for the inference of haplotypes not previously observed (reviewed in Reference 59). The Bayesian algorithms perform better than the parsimony and maximum-likelihood algorithms (58) . Like other algorithms, Bayesian approaches do not account for recurrent mutation or gene conversion.
The main disadvantage of all statistical-inference packages is that a proportion of the inferred haplotypes may be incorrect (58) (59) (60) (61) . For example, singleton haplotypes can never be resolved in this way. This uncertainty in constructing haplotypes will ultimately lead to a loss of power in testing for an association with a disease. In attempts to quantify the inaccuracies of these algorithms, several studies have compared inferred haplotypes with molecularly determined haplotypes in the same genes. These studies demonstrate that most algorithms can estimate overall haplotype frequencies well (62) (63) (64) for datasets with few or no genotyping errors (65) . However, the accuracy of individual haplotypes varies. It is particularly difficult to assign rare sites to a chromosome (58) , and at least one study demonstrates that the accuracy of haplotype inference is higher for common sites than for rare sites (66) . Uncertainty in haplotype inference can be incorporated into tests for association by using haplotypes to locate genes responsible for Mendelian diseases, but this may not be the best strategy for mapping genes responsible for complex traits (67) .
Haplotypes and the Clinic
Human leuokocyte antigen (HLA) matching is a clear example of how haplotypes can be used in the clinic to improve outcome. In this scenario, transplant recipients and donors are genotyped at several markers along the major histocompatibility complex. The HLA haplotypes are then determined by ordering the alleles along the chromosomes. Patients who match the donor haplotypes closely are predicted to have a better transplant outcome than patients who do not. The development of HLA haplotype matching has proved to be crucial in making transplantation between unrelated patients and donors a success (reviewed in Reference 68) .
At present, with the exception of HLA matching in bone marrow transplants (68), haplotypes are generally not used in the clinical setting because they do not offer greater clinical validity or utility than directly assaying causative mutations or biochemical markers. However, there are instances in which haplotypes rather than genotypes at a single locus can predict severity of disease. For example, some research suggests that a specific β-globin locus haplotype is associated with less severe sickle cell disease phenotypes (69, 70) . More recently, a promoter region haplotype in IL10 was associated with a lower incidence of graft-versushost disease and death compared with other haplotypes among patients receiving hematopoietic-cell transplants (43). Finally, examples are emerging in which haplotypes (several cis-acting sites) rather than single sites alone are required to produce the phenotype or impact the gene product (71, 72) . The best-known example may be the cholesterol-related protein alleles at the ApoE locus, which involve two amino acid substitutions and perhaps complementing effects at regulatory regions flanking the gene (73) . Though tantalizing, these results require extensive followup before both SNPs and haplotypes are considered useful and incorporated into extensive genetic testing profiles (74, 75) .
An exciting focus of research in which haplotypes could also demonstrate significant clinical validity and utility is in the field of pharmacogenomics. It is well known that individual variation in drug response can be attributed to specific genetic variants (76) (77) (78) . Examples of haplotypes used in studies to predict drug response include the β-2 adrenergic receptor (ADRB2) haplotypes related to β-agonist response in asthmatics (71) and major histocompatibility haplotypes related to abacavir hypersensitivity in HIV-infected patients (79) . Incorporation of haplotypes into studies of pharmacogenetics will certainly increase in the near future and provide a more complete picture of the sites that are relevant, either alone or in concert, in the practice of "genetic medicine" at the population or individual level (80, 81) .
Haplotypes and Candidate Genes
In the research setting, haplotypes are commonly used to localize a diseaseconferring gene or locus. Currently, much interest surrounds the use of genetic association studies because this study design is suggested to be more powerful than linkage studies in localizing susceptibility loci for common diseases (e.g., heart disease, asthma, diabetes, autoimmune disease, or cancer) that confer moderate risk (32) . Some authors have argued that the linkage-or family-based approaches are more powerful and appropriate than association studies for studying complex, common diseases (82) , and the issue remains an active area of scientific debate. Like the linkage study design, an association study design genotypes markers in affected and unaffected individuals, and it is expected that markers that co-occur or are associated with the disease phenotype either contribute to the phenotype or are associated with the disease susceptibility locus. Although both study designs rely on recombination to narrow the region that might contain a causative locus, each study takes a different approach in measuring recombinants among the study subjects. In a linkage study, specific recombination events can be directly measured within families because recombination separates genotyped markers from the disease locus if they are not physically close to the disease locus. In an association study, recombination is measured indirectly through linkage disequilibrium, a reflection or product of historic recombination over time in distantly related individuals (i.e., a population; reviewed in Reference 83).
In a candidate gene association study, a gene is chosen for study based on an educated guess of the location (usually by a linkage study), genetic studies in model organisms, or the biology of the disease locus in relation to the disease phenotype. The specific role of haplotypes in a candidate gene association study depends on the hypothesis being tested. For example, haplotypes can represent a combined effect of several sites along the same chromosome (cis-acting loci) that cannot be detected when these sites are tested one by one. In some cases, linkage disequilibrium is so high (i.e., neighboring sites are always associated with one another) that the effects of each variant in a haplotype cannot be identified, and haplotypes do not provide the required resolution (3, 4) . More commonly, investigators rely on haplotypes to serve as proxies for ungenotyped SNPs. In this case, for a traditional case-control gene association study design, a statistical test is performed to determine if an allele or genotype of a SNP in a particular candidate gene is over-represented among cases compared with controls. If a SNP allele is associated with a disease phenotype, the allele is either contributing to the disease phenotype or is in linkage disequilibrium with the SNP allele that contributes to the phenotype. A falsepositive association could also arise from population stratification (a situtation where allele frequencies differ among population subdivisions within the case and control samples), improper case-control matching, or, more likely, multiple testing and chance (reviewed in References 84 and 85). The same holds true for haplotypes; a positive association with a haplotype could indicate that a site not directly genotyped but associated with other alleles along the same chromosome (haplotype) accounts for the phenotype. Often the latter possibility cannot be ruled out because comprehensive detail of sequence variation of the candidate gene is not known. In this scenario, the investigator must perform further variation discovery and genotyping to determine the extent of the haplotype association in the study population. In the event that complete sequence variation is known, if there is too much linkage disequilibrium, individual SNP effects may remain unresolved despite the investigator's best efforts to tease them apart.
Haplotype Tagging
This incomplete approach to testing candidate genes in a genetic association study is now being replaced with a more comprehensive approach. With the advent of high-throughput variation discovery, more and more markers useful for genetic association studies are being mapped to candidate genes and deposited into public databases. Furthermore, detailed views of fine-scale variation in recombination (86, 87) and linkage disequilibrium (88) have been determined for many candidate genes. However, even though the costs associated with genotyping have improved, the number of markers now available per gene makes genotyping all markers very expensive for the average research budget. Because of this, much interest has developed in choosing a set of markers to genotype that would eliminate redundant markers (i.e., markers in strong linkage disequilibrium with other markers) and would best represent the genetic variation of the candidate gene of interest.
One approach for choosing markers for genotyping is known as haplotype tagging (Figure 2) . In studies that use this approach, SNPs that uniquely identify common haplotypes (>5% in frequency) are determined and genotyped to identify the common haplotypes (89) . Since the introduction of haplotype tagging and the identification of "htSNPs" or "tagSNPs," several statistical methods have been developed to identify SNPs that capture the haplotype diversity (e.g., References 90 and 91) observed in the population (Table 3 ). An encouraging aspect of haplotype tagging is that only a small subsample of the study population needs to be assessed for the identification of the tagSNPs (92, 93) , making this strategy efficient as well as economical. However, many current approaches do have limitations. Many algorithms require haplotypes (90) but do not account for incorrectly inferred haplotypes (91) . Furthermore, these algorithms assume that the haplotypes conform to a block-like pattern (90) or impose a block-like pattern as part of the algorithm (91) . The definition of haplotype blocks and their limitations for use in genetic association studies are discussed below. Another limitation of haplotype tagging is that many candidate genes and genomic regions have many haplotypes. Previously, preliminary reports suggested that candidate genes have a few common haplotypes per gene (10) . However, the sequence data behind these reports were derived primarily from exons. A recent analysis of data derived from complete resequencing of genes demonstrated that the number of haplotypes per gene varies greatly. Furthermore, several of the genes examined did not have a single haplotype with an estimated population frequency >5% (94) . The variability in haplotype diversity across candidate genes can potentially limit the efficiency of haplotype tagging algorithms, depending on the candidate gene being studied. Because of these limitations, it may be more practical to choose tagSNPs by using linkage disequilibrium on sequence data rather than inferred haplotypes (29) .
In general, tagSNPs determined by haplotype-and linkage-disequilibriumbased methods are similar because these methods represent the same cladistic or evolutionary history of the gene or region being examined (95) . The methods are particularly similar for genes with simple haplotype structures (29) ; however, for genes with complex haplotype architectures and possible hotspots of recombination (86, 87) , a linkage-disequilibrium-based method for choosing tagSNPs may more efficient. Regardless of the method chosen for SNP selection, it is important to keep in mind that genotyping a subset of SNPs may or may not represent the haplotype architecture observed when variation from the entire sequence is considered; thus, more SNPs may be ultimately required even when a subset is carefully chosen (94, 95) .
One limitation shared by both haplotype-and linkage-disequilibrium-based methods for choosing tagSNPs is the population specificity of the tagSNPs (29) . More specifically, tagSNPs chosen in one population (e.g., a European-descent population) are not appropriate for genotyping in a different population (e.g., an African-descent population) (95) . Although populations do share a proportion of haplotypes, there are differences in frequencies (94) that may be important in an association study. Also, investigators should be aware that population stratification inflates estimates of linkage disequilibrium (reviewed in Reference 96); therefore, populations of combined race or ethnicity (e.g., the Polymorphism Discovery Resource Panel) (97) are not ideal for choosing tagSNPs to be genotyped in larger populations. To avoid this problem, many advocate determining if complete variation discovery has been performed in the candidate gene using a population similar to the study population and recommend that tagSNPs be selected from these data rather than from a database (which is probably biased toward Europeans) (18) or another population of a different racial/ethnic group.
Whole-Genome Association Studies and the HapMap
As mentioned above, the case-control genetic association study can be a powerful study design to identify significant association between a variant and a phenotype for variants that confer moderate risk. A disadvantage of this study design is the fact that the investigator must make an initial decision regarding which gene or region to investigate. The whole-genome association study design requires no initial guess of the causative gene(s). In a sense, much like a linkage study design, the entire genome is being tested for a relationship between a marker and a phenotype. This is an example of an "indirect" approach because the investigator is relying on linkage disequilibrium between the (presumably) nonfunctional or functionally unrelated marker being genotyped and the true causative SNP (33) . However, the number of markers that must be genotyped is much greater than in a linkage study, with estimates ranging from 170,000 to more than 1 million depending on the extent of linkage disequilibrium in the population (98) (99) (100) .
Because of the sheer numbers of SNPs needed for whole-genome association studies, investigators are interested in methods that help determine the optimal set of SNPs to genotype. Recently, much attention has been given to the identification of haplotype blocks and their potential usefulness in whole-genome association studies. The concept of "blocks" arose from studies in which a candidate gene (101) , an entire chromosome (52), or large regions of the genome (102) were genotyped in moderate-sized populations. Generally, as the number of markers increases, the number of haplotypes necessarily increases, eventually forming haplotypes that are unique to individuals (their chromosomes). Daly et al. (102) noted that the 500-kb region of 5q31 genotyped in a European-descent population had discrete regions of low haplotype diversity. The regions, termed blocks, were up to 100 kb long and generally consisted of 2-4 haplotypes that accounted for >90% of the chromosomes surveyed. Within the blocks, there was evidence of little to no recombination (resulting in high linkage disequilibrium), and between the blocks, there was evidence of a clustering of recombination events (resulting in a breakdown in linkage disequilibrium). Along with preliminary supporting experimental evidence (103) , these findings suggested that hotspots of recombination form the boundaries of haplotype blocks (102) . Following these reports, Gabriel et al. (100) formalized a definition of haplotype blocks using D , a measure of linkage disequilibrium, and demonstrated that haplotype blocks existed across the human genome in several populations.
The main advantage of low haplotype diversity or haplotype blocks is that only a few tagSNPs need to be genotyped to represent haplotypes within a block in a whole-genome association study [see Figure 3 (color insert) for an example]. Fueled by the prospect that the human genome can be described in terms of haplotype blocks, the National Human Genome Research Institute (NHGRI) at the National Institutes of Health (NIH) initiated the International "HapMap" Project. The goal of the HapMap is to describe common DNA variation (frequency, linkage disequilibrium patterns, etc.) across the genome and to make these data available for researchers interested in whole-genome association studies (104) . To do this, the International HapMap Consortium proposes a hierarchical approach of genotyping and analysis. That is, the Consortium will genotype ∼600,000 SNPs that have a minor allele frequency of >5% and are spaced approximately every 5 kb in several populations (European, African, and Asian), using validated SNPs available in databases. The data will then by analyzed by several methods, including the haplotype block approach, and regions of little or no linkage disequilibrium will be marked for further genotyping and characterization. It is expected that nearly 3 million SNPs will be genotyped in this major collaborative effort, generating a denser map for whole-genome association studies.
The creation of the HapMap will undoubtedly enrich specific areas of research, both immediately and long-term. Already, much has been learned about the blocklike nature of the human genome that can be applied to whole-genome association study design and analysis. For example, although several studies have also noted block-like structure across regions of the genome other than 5q31 (105, 106) , the boundaries of the blocks could have been generated by other forces (such as population history) rather than by hotspots of recombination (106, 107) . The idea that other forces may affect block boundaries and size has important implications for determining the number of SNPs required for whole-genome associations in diverse populations. Indeed, it is well noted that African-descent populations have a greater number of short blocks than do European-descent populations (reviewed in Reference 88); thus, a denser map is needed for Africandescent populations. Also, Wall & Pritchard (108) recently determined in several populations that although the human genome does exhibit block-like structure, the conformity to "blockiness" is uneven. Several groups have noted that the number and/or sizes of the blocks depend on the SNP density (109), the minor allele frequency cut-off imposed on the dataset (110, 111) , and the algorithm used to define blocks (112) . Collectively, these preliminary studies, coupled with the inevitable development of cost-effective technologies for large-scale genotyping and further detailed studies of patterns of linkage disequilibrium in diverse populations, will ensure that the International HapMap Project becomes a useful public tool in the search for disease-causing genes and loci important in public health (104) .
SUMMARY
Haplotypes represent sequences along the chromosome that are either preserved intact or separated by recombination over time. This basic concept has led to the development of methods that extract information about recombination to aid investigators in localizing disease-causing genes and loci. Linkage studies have been successful in the past in identifying rare disease-causing mutations within families. Association studies have been less successful in identifying loci responsible for common disease. To identify these loci, additional research is required to develop high-throughput methods to construct unambiguous haplotypes or methods that allow us to accurately infer haplotypes. Furthermore, new statistical methods are required to fully utilize haplotypes in whole-genome association studies. Finally, a new understanding of the biology of common disease must be achieved to meaningfully link individual genotypes to complex phenotypes. The International HapMap Project seeks to provide many of the tools currently missing for whole-genome studies, and much research both within and outside this project is beginning to bridge the gap between basic research and the translation of this research into medical care informed by human genetics.
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